Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AZTR
Upturn stock ratingUpturn stock rating

Azitra Inc (AZTR)

Upturn stock ratingUpturn stock rating
$0.69
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

10/13/2025: AZTR (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $4.5

1 Year Target Price $4.5

Analysts Price Target For last 52 week
$4.5 Target price
52w Low $0.68
Current$0.69
52w High $4.33

Analysis of Past Performance

Type Stock
Historic Profit 0%
Avg. Invested days 0
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 10/13/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.73M USD
Price to earnings Ratio 0.03
1Y Target Price 4.5
Price to earnings Ratio 0.03
1Y Target Price 4.5
Volume (30-day avg) 1
Beta -1.69
52 Weeks Range 0.68 - 4.33
Updated Date 10/13/2025
52 Weeks Range 0.68 - 4.33
Updated Date 10/13/2025
Dividends yield (FY) -
Basic EPS (TTM) 26.97

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -180.76%
Return on Equity (TTM) -473.31%

Valuation

Trailing PE 0.03
Forward PE -
Enterprise Value 3515590
Price to Sales(TTM) 438.62
Enterprise Value 3515590
Price to Sales(TTM) 438.62
Enterprise Value to Revenue 10.99
Enterprise Value to EBITDA -0.39
Shares Outstanding 5404968
Shares Floating 3506751
Shares Outstanding 5404968
Shares Floating 3506751
Percent Insiders 0.52
Percent Institutions 1.71

ai summary icon Upturn AI SWOT

Azitra Inc

stock logo

Company Overview

overview logo History and Background

Azitra, Inc. is a clinical-stage medical dermatology company focused on developing therapies to protect skin health using its proprietary platform that combines a deep understanding of the skin microbiome with innovative genetic engineering. They were founded in 2014 and went public through a special-purpose acquisition company (SPAC) merger in 2023.

business area logo Core Business Areas

  • Therapeutic Development: Azitra focuses on developing genetically engineered bacteria to treat skin conditions and diseases.
  • Research and Development: The company invests in research to expand its understanding of the skin microbiome and develop new therapeutic candidates.

leadership logo Leadership and Structure

Travis Whitfill is the CEO. The company has a board of directors and is structured around research, development, and clinical operations.

Top Products and Market Share

overview logo Key Offerings

  • ATR-12: ATR-12 is a genetically engineered strain of Staphylococcus epidermidis being developed for Netherton Syndrome. Currently in phase 1b trials. Competitors include companies developing gene therapies and biologics for similar genetic skin disorders, such as Novartis.
  • ATR-04: ATR-04 is being developed to treat papulopustular rosacea. Competitors include companies focused on topical treatments for rosacea. Precise market share data is not currently available.

Market Dynamics

industry overview logo Industry Overview

The medical dermatology industry is growing, driven by increasing awareness of skin conditions and the development of new treatments. The market is competitive, with a mix of established pharmaceutical companies and smaller biotech firms.

Positioning

Azitra is positioned as an innovator in the skin microbiome therapeutic space, with a focus on genetically engineered bacteria. Their competitive advantage lies in their proprietary platform and focus on targeted therapies.

Total Addressable Market (TAM)

The total addressable market for Netherton Syndrome and rosacea therapeutics is estimated to be in the billions of dollars. Azitra is positioned to capture a portion of this market with its novel approach, however, this is highly speculative at this early stage.

Upturn SWOT Analysis

Strengths

  • Proprietary platform technology
  • Focus on unmet medical needs
  • Strong scientific team
  • Potential for first-in-class therapies

Weaknesses

  • Early stage of development
  • High risk associated with novel therapies
  • Dependence on external funding
  • Limited clinical data

Opportunities

  • Expanding pipeline of therapeutic candidates
  • Partnering with larger pharmaceutical companies
  • Securing regulatory approvals
  • Addressing additional skin conditions

Threats

  • Competition from established companies
  • Regulatory hurdles
  • Clinical trial failures
  • Intellectual property challenges

Competitors and Market Share

competitor logo Key Competitors

  • NOVN
  • SNY
  • LLY

Competitive Landscape

Azitra competes with established pharmaceutical companies and smaller biotech firms in the dermatology space. Their advantage lies in their unique approach to targeting the skin microbiome.

Growth Trajectory and Initiatives

Historical Growth: Azitra's historical growth has been focused on preclinical and early-stage clinical development.

Future Projections: Future growth is dependent on successful clinical trials and regulatory approvals. Analyst estimates are unavailable.

Recent Initiatives: Recent initiatives include advancing ATR-12 into Phase 1b trials and expanding the pipeline with ATR-04.

Summary

Azitra is an early-stage biotech company with a novel approach to treating skin diseases using engineered bacteria. Their success depends on positive clinical trial results and securing regulatory approvals. While their technology is promising, they face significant risks associated with drug development and competition from established players. More information on their market cap will impact the fundamental rating.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Press Releases
  • Industry Reports

Disclaimers:

This analysis is based on publicly available information and should not be considered financial advice. The information provided is not guaranteed to be accurate or complete. Investing in early-stage biotech companies involves significant risks.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Azitra Inc

Exchange NYSE MKT
Headquaters Branford, CT, United States
IPO Launch date 2023-06-16
President, CEO & Director Mr. Francisco D. Salva
Sector Healthcare
Industry Biotechnology
Full time employees 12
Full time employees 12

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.